A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria

• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• •Life expectancy at least 12 weeks
• •Adequate hematologic and end organ function
• •Negative pregnancy test and willingness to utilize contraception among women of childbearing potential
• •Locally advanced, recurrent, or metastatic incurable solid malignancy with measurable disease per RECIST v1.1
• •Progression following at least one standard therapy; or standard therapy considered ineffective, intolerable, or inappropriate; or use of an investigational agent recognized as a standard of care
• •For the expansion stage, histologically confirmed renal cell cancer (RCC), urothelial bladder cancer (UBC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), gastric cancer, ovarian cancer, cervical cancer, endometrial cancer, or Merkel cell cancer
• •For the expansion stage, evaluable for PD-L1 expression
• •Anti PD-1/PD-L1 relapsed cohorts (I and II), participants whose most recent anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade will be enrolled